Market Research

Central Nervous System (CNS) Therapeutics Market (Drug Class: Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives and Hypnotics, Anti-Depressants, and Others; and Disease Type: Neurodegenerative Disorders, Mental Health, Neurovascular Diseases

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 174 Pages Transparency Market Research Pvt. Ltd. May, 2024 TNPR18955057
Best Price Guarantee
Price from $5,795
Length 174 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date May, 2024
SKU TNPR18955057

Central Nervous System (CNS) Therapeutics Market (Drug Class: Analgesics, Anti-Cholinergic Agents, Anticonvulsants, Sedatives and Hypnotics, Anti-Depressants, and Others; and Disease Type: Neurodegenerative Disorders, Mental Health, Neurovascular Diseases, CNS Trauma, CNS Cancer, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034


Central Nervous System (CNS) Therapeutics Market – Scope of Report

TMR’s report on the global central nervous system (CNS) therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global central nervous system (CNS) therapeutics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global central nervous system (CNS) therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the central nervous system (CNS) therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global central nervous system (CNS) therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global central nervous system (CNS) therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global central nervous system (CNS) therapeutics market.

The report delves into the competitive landscape of the global central nervous system (CNS) therapeutics market. Key players operating in the global central nervous system (CNS) therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global central nervous system (CNS) therapeutics market profiled in this report.

Key Questions Answered in Global central nervous system (CNS) therapeutics Market Report
  • What is the sales/revenue generated by central nervous system (CNS) therapeutics across all regions during the forecast period?
  • What are the opportunities in the global central nervous system (CNS) therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Central Nervous System (CNS) Therapeutics Market – Research Objectives and Research Approach

The comprehensive report on the global central nervous system (CNS) therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global central nervous system (CNS) therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global central nervous system (CNS) therapeutics market.


1. Preface
  1.1. Market Definition and Scope
  1.2. Market Segmentation
  1.3. Key Research Objectives
  1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Central Nervous System (CNS) Therapeutics Market
4. Market Overview
  4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
  4.2. Overview
  4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
  4.4. Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
  5.1. Pipeline Analysis
  5.2. Key Product /Brand Analysis
  5.3. Key Mergers & Acquisitions
  5.4. COVID-19 Pandemic Impact on Industry
6. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Drug Class
  6.1. Introduction & Definition
  6.2. Key Findings/Developments
  6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Analgesics
6.3.2. Anti-Cholinergic Agents
6.3.3. Anticonvulsants
6.3.4. Sedatives and Hypnotics
6.3.5. Anti-Depressants
6.3.6. Others (Antipsychotics, etc.)
  6.4. Market Attractiveness Analysis, by Drug Class
7. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Disease Type
  7.1. Introduction & Definition
  7.2. Key Findings/Developments
  7.3. Market Value Forecast, by Disease Type, 2020-2034
7.3.1. Neurodegenerative Disorders
7.3.1.1. Alzheimer’s Disease
7.3.1.2. Parkinson’s Disease
7.3.1.3. Huntington’s Disease
7.3.1.4. Amyotrophic Lateral Sclerosis
7.3.1.5. Others (Multiple Sclerosis, etc.)
7.3.2. Mental Health
7.3.2.1. Anxiety Disorders
7.3.2.2. Epilepsy
7.3.2.3. Psychotic Disorders
7.3.2.4. Others (Mood Disorders, etc.)
7.3.3. Neurovascular Diseases
7.3.4. CNS Trauma
7.3.5. CNS Cancer
7.3.6. Others (Infectious Disorders, etc.)
  7.4. Market Attractiveness Analysis, by Disease Type
8. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Distribution Channel
  8.1. Introduction & Definition
  8.2. Key Findings/Developments
  8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
  8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Region
  9.1. Key Findings
  9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
  9.3. Market Attractiveness Analysis, by Region
10. North America Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
  10.1. Introduction
  10.2. Key Findings
  10.3. Market Value Forecast, by Drug Class, 2020-2034.
10.3.1. Analgesics
10.3.2. Anti-Cholinergic Agents
10.3.3. Anticonvulsants
10.3.4. Sedatives and Hypnotics
10.3.5. Anti-Depressants
10.3.6. Others (Antipsychotics, etc.)
  10.4. Market Value Forecast, by Disease Type, 2020-2034.
10.4.1. Neurodegenerative Disorders
10.4.1.1. Alzheimer’s Disease
10.4.1.2. Parkinson’s Disease
10.4.1.3. Huntington’s Disease
10.4.1.4. Amyotrophic Lateral Sclerosis
10.4.1.5. Others (Multiple Sclerosis, etc.)
10.4.2. Mental Health
10.4.2.1. Anxiety Disorders
10.4.2.2. Epilepsy
10.4.2.3. Psychotic Disorders
10.4.2.4. Others (Mood Disorders, etc.)
10.4.3. Neurovascular Diseases
10.4.4. CNS Trauma
10.4.5. CNS Cancer
10.4.6. Others (Infectious Disorders, etc.)
  10.5. Market Value Forecast, by Distribution Channel, 2020-2034.
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
  10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
  10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Disease Type
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
  11.1. Introduction
  11.2. Key Findings
  11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. Analgesics
11.3.2. Anti-Cholinergic Agents
11.3.3. Anticonvulsants
11.3.4. Sedatives and Hypnotics
11.3.5. Anti-Depressants
11.3.6. Others (Antipsychotics, etc.)
  11.4. Market Value Forecast, by Disease Type, 2020-2034.
11.4.1. Neurodegenerative Disorders
11.4.1.1. Alzheimer’s Disease
11.4.1.2. Parkinson’s Disease
11.4.1.3. Huntington’s Disease
11.4.1.4. Amyotrophic Lateral Sclerosis
11.4.1.5. Others (Multiple Sclerosis, etc.)
11.4.2. Mental Health
11.4.2.1. Anxiety Disorders
11.4.2.2. Epilepsy
11.4.2.3. Psychotic Disorders
11.4.2.4. Others (Mood Disorders, etc.)
11.4.3. Neurovascular Diseases
11.4.4. CNS Trauma
11.4.5. CNS Cancer
11.4.6. Others (Infectious Disorders, etc.)
  11.5. Market Value Forecast, by Distribution Channel, 2020-2034.
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
  11.6. Market Value Forecast, by Distribution Channel, 2020-2034.
11.6.1. Hospitals
11.6.2. Biopharmaceutical Companies
11.6.3. Research Organizations and Academic Institutes
  11.7. Market Value Forecast, by Country/Sub-region, 2020-2034
11.7.1. Germany
11.7.2. U.K.
11.7.3. France
11.7.4. Italy
11.7.5. Spain
11.7.6. Rest of Europe
  11.8. Market Attractiveness Analysis
11.8.1. By Drug Class
11.8.2. By Disease Type
11.8.3. By Distribution Channel
11.8.4. By Country/Sub-region
12. Asia Pacific Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
  12.1. Introduction
  12.2. Key Findings
  12.3. Market Value Forecast, by Drug Class, 2020-2034.
12.3.1. Analgesics
12.3.2. Anti-Cholinergic Agents
12.3.3. Anticonvulsants
12.3.4. Sedatives and Hypnotics
12.3.5. Anti-Depressants
12.3.6. Others (Antipsychotics, etc.)
  12.4. Market Value Forecast, by Disease Type, 2020-2034.
12.4.1. Neurodegenerative Disorders
12.4.1.1. Alzheimer’s Disease
12.4.1.2. Parkinson’s Disease
12.4.1.3. Huntington’s Disease
12.4.1.4. Amyotrophic Lateral Sclerosis
12.4.1.5. Others (Multiple Sclerosis, etc.)
12.4.2. Mental Health
12.4.2.1. Anxiety Disorders
12.4.2.2. Epilepsy
12.4.2.3. Psychotic Disorders
12.4.2.4. Others (Mood Disorders, etc.)
12.4.3. Neurovascular Diseases
12.4.4. CNS Trauma
12.4.5. CNS Cancer
12.4.6. Others (Infectious Disorders, etc.)
  12.5. Market Value Forecast, by Distribution Channel, 2020-2034.
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
  12.6. Market Value Forecast, by Distribution Channel, 2020-2034.
12.6.1. Hospitals
12.6.2. Biopharmaceutical Companies
12.6.3. Research Organizations and Academic Institutes
  12.7. Market Value Forecast, by Country/Sub-region, 2020-2034
12.7.1. China
12.7.2. Japan
12.7.3. India
12.7.4. Australia & New Zealand
12.7.5. Rest of Asia Pacific
  12.8. Market Attractiveness Analysis
12.8.1. By Drug Class
12.8.2. By Disease Type
12.8.3. By Distribution Channel
12.8.4. By Country/Sub-region
13. Latin America Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
  13.1. Introduction
  13.2. Key Findings
  13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. Analgesics
13.3.2. Anti-Cholinergic Agents
13.3.3. Anticonvulsants
13.3.4. Sedatives and Hypnotics
13.3.5. Anti-Depressants
13.3.6. Others (Antipsychotics, etc.)
  13.4. Market Value Forecast, by Disease Type, 2020-2034.
13.4.1. Neurodegenerative Disorders
13.4.1.1. Alzheimer’s Disease
13.4.1.2. Parkinson’s Disease
13.4.1.3. Huntington’s Disease
13.4.1.4. Amyotrophic Lateral Sclerosis
13.4.1.5. Others (Multiple Sclerosis, etc.)
13.4.2. Mental Health
13.4.2.1. Anxiety Disorders
13.4.2.2. Epilepsy
13.4.2.3. Psychotic Disorders
13.4.2.4. Others (Mood Disorders, etc.)
13.4.3. Neurovascular Diseases
13.4.4. CNS Trauma
13.4.5. CNS Cancer
13.4.6. Others (Infectious Disorders, etc.)
  13.5. Market Value Forecast, by Distribution Channel, 2020-2034.
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
  13.6. Market Value Forecast, by Distribution Channel, 2020-2034.
13.6.1. Hospitals
13.6.2. Biopharmaceutical Companies
13.6.3. Research Organizations and Academic Institutes
  13.7. Market Value Forecast, by Country/Sub-region, 2020-2034
13.7.1. Brazil
13.7.2. Mexico
13.7.3. Rest of Latin America
  13.8. Market Attractiveness Analysis
13.8.1. By Drug Class
13.8.2. By Disease Type
13.8.3. By Distribution Channel
13.8.4. By Country/Sub-region
14. Middle East & Africa Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
  14.1. Introduction
  14.2. Key Findings
  14.3. Market Value Forecast, by Drug Class, 2020-2034
14.3.1. Analgesics
14.3.2. Anti-Cholinergic Agents
14.3.3. Anticonvulsants
14.3.4. Sedatives and Hypnotics
14.3.5. Anti-Depressants
14.3.6. Others (Antipsychotics, etc.)
  14.4. Market Value Forecast, by Disease Type, 2020-2034.
14.4.1. Neurodegenerative Disorders
14.4.1.1. Alzheimer’s Disease
14.4.1.2. Parkinson’s Disease
14.4.1.3. Huntington’s Disease
14.4.1.4. Amyotrophic Lateral Sclerosis
14.4.1.5. Others (Multiple Sclerosis, etc.)
14.4.2. Mental Health
14.4.2.1. Anxiety Disorders
14.4.2.2. Epilepsy
14.4.2.3. Psychotic Disorders
14.4.2.4. Others (Mood Disorders, etc.)
14.4.3. Neurovascular Diseases
14.4.4. CNS Trauma
14.4.5. CNS Cancer
14.4.6. Others (Infectious Disorders, etc.)
  14.5. Market Value Forecast, by Distribution Channel, 2020-2034.
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
  14.6. Market Value Forecast, by Distribution Channel, 2020-2034.
14.6.1. Hospitals
14.6.2. Biopharmaceutical Companies
14.6.3. Research Organizations and Academic Institutes
  14.7. Market Value Forecast, by Country/Sub-region, 2020-2034
14.7.1. GCC Countries
14.7.2. South Africa
14.7.3. Rest of Middle East & Africa
  14.8. Market Attractiveness Analysis
14.8.1. By Drug Class
14.8.2. By Disease Type
14.8.3. By Distribution Channel
14.8.4. By Country/Sub-region
15. Competition Landscape
  15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  15.2. Market Share Analysis, by Company (2023)
  15.3. Company Profiles
15.3.1. Biogen
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Otsuka Pharmaceutical Co., Ltd.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Eli Lilly and Company
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co. Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. AstraZeneca
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Novartis AG
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Teva Pharmaceutical Industries Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Pfizer Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Takeda Pharmaceuticals
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Johnson & Johnson Services, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings